Impaired osteoclast homeostasis in the cystatin B-deficient mouse model of progressive myoclonus epilepsy  by Manninen, Otto et al.
Bone Reports 3 (2015) 76–82
Contents lists available at ScienceDirect
Bone Reports
j ourna l homepage: www.e lsev ie r .com/ locate /bonrImpaired osteoclast homeostasis in the cystatin B-deﬁcientmousemodel
of progressive myoclonus epilepsyOtto Manninen a,b,c,⁎, Tero Puolakkainen d, Jemina Lehto d, Elina Harittu e, Aki Kallonen f, Marko Peura f,
Tiina Laitala-Leinonen e, Outi Kopra a,b,c, Riku Kiviranta f, Anna-Elina Lehesjoki a,b,c
a Folkhälsan Institute of Genetics, 00290 Helsinki, Finland
b Research Program's Unit, Molecular Neurology, University of Helsinki, 00014 Helsinki, Finland
c Neuroscience Center, University of Helsinki, 00014 Helsinki, Finland
d Department of Medicine, University of Turku, 20520 Turku, Finland
e Department of Anatomy, University of Turku, 20520 Turku, Finland
f Department of Physics, University of Helsinki, 00014 Helsinki, FinlandAbbreviations: CSTB, cystatin B; EPM1, progressivemy
Lundborg type; μCT, micro-computed tomography.
⁎ Corresponding author at: Folkhälsan Institute of Gen
FIN-00014, Finland.
E-mail address: otto.manninen@helsinki.ﬁ (O. Mannin
http://dx.doi.org/10.1016/j.bonr.2015.10.002
2352-1872/© 2015 The Authors. Published by Elsevier Inca b s t r a c ta r t i c l e i n f oArticle history:
Received 19 May 2015
Received in revised form 19 September 2015
Accepted 4 October 2015
Available online 6 November 2015
Keywords:
Cystatin B,
Cathepsin K,
Osteoclast,
Osteogenesis,
Micro-computed tomography,
Progressive myoclonus epilepsyProgressive myoclonus epilepsy of Unverricht–Lundborg type (EPM1) is an autosomal recessively inherited dis-
order characterized by incapacitating stimulus-sensitive myoclonus and tonic-clonic epileptic seizures with
onset at the age of 6 to 16 years. EPM1 patients also exhibit a range of skeletal changes, e.g., thickened frontal cra-
nial bone, arachnodactyly and scoliosis. Mutations in the gene encoding cystatin B (CSTB) underlie EPM1. CSTB is
an inhibitor of cysteine cathepsins, including cathepsin K, a key enzyme in bone resorption by osteoclasts. CSTB
has previously been shown to protect osteoclasts from experimentally induced apoptosis and to modulate bone
resorption in vitro. Nevertheless, its physiological function in bone and the cause of the bone changes in patients
remain unknown. Herewe used the CSTB-deﬁcientmouse (Cstb−/−)model of EPM1 to evaluate the contribution
of defective CSTB protein function on bone pathology and osteoclast differentiation and function. Micro-comput-
ed tomography of hind limbs revealed thicker trabeculae and elevated bone mineral density in the trabecular
bone of Cstb−/−mice. Histology from Cstb−/−mouse bones showed lower osteoclast count and thinner growth
plates in long bones. Bone marrow-derived osteoclast cultures revealed lower osteoclast number and size in the
Cstb−/− group. Cstb−/− osteoclasts formed less and smaller resorption pits in an in vitro assay. This impaired re-
sorptive capacity was likely due to a decrease in osteoclast numbers and size. These data imply that the skeletal
changes in Cstb−/−mice and in EPM1 patients are a result of CSTB deﬁciency leading to impaired osteoclast for-
mation and consequently compromised resorptive capacity. These results suggest that the role of CSTB in osteo-
clast homeostasis and modulation of bone metabolism extends beyond cathepsin K regulation.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).1. Introduction
Progressive myoclonus epilepsy of Unverricht–Lundborg type
(EPM1, OMIM254800, progressivemyoclonus epilepsy type 1) is an au-
tosomal recessively inherited neurodegenerative disorder with onset at
the age of 6–16 years. Themain symptoms include severely incapacitat-
ing action myoclonus, tonic-clonic epileptic seizures and ataxia
(Koskiniemi et al., 1974, Kälviäinen et al., 2008). Other central ﬁndings
include progressive gray and white matter degeneration and changes
in cortical excitability (Koskenkorva et al., 2009, Koskenkorva et al.,oclonus epilepsy of Unverricht–
etics, University of Helsinki, 63,
en).
. This is an open access article under2012, Danner et al., 2013,Manninen et al., 2013). In addition to the neu-
rological features, EPM1 patients have heterogeneous bone ﬁndings
(Korja et al., 2007, Suoranta et al., 2012, Danner et al., 2013). They exhib-
it diffuse thickening of cranial bones in headmagnetic resonance imag-
ing (Suoranta et al., 2012). Evaluation of digital head computed
tomography (CT) scans have implied osteoporotic bone structure, but,
bone mineral density has not been systematically determined
(Suoranta et al., 2012). The majority of EPM1 patients also show other
skeletal changes, most commonly arachnodactyly, scoliosis, enlarged si-
nuses, and accessory ossicles of the foot (Suoranta et al., 2012), the eti-
ology of which is currently unknown.
EPM1 is caused by loss-of-function mutations in the CSTB gene
encoding cystatin B (CSTB), an inhibitor of lysosomal cysteine cathep-
sins, including cathepsin K (Pennacchio et al., 1996, Lalioti et al.,
1997). A mouse model (Cstb−/−) of the EPM1 disease has been created
with targeted disruption of the Cstb gene. The mouse modelthe CC BY license (http://creativecommons.org/licenses/by/4.0/).
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progressive ataxia (Pennacchio et al., 1998). Pathological ﬁndings in
Cstb−/−mice match those in the patients: the mice exhibit progressive
loss in brain volume due to neuronal death and consequent white mat-
ter atrophy in the cerebrum and cerebellum (Tegelberg et al., 2012,
Manninen et al., 2013, 2014). The earliest pathological ﬁnding in
Cstb−/− mice is striking microglial activation present at postnatal day
14 and preceding the onset of myoclonus and progressive neuronal de-
generation from 1 month of age onwards (Tegelberg et al., 2012).
Bone resorbing osteoclasts and bone forming osteoblasts continu-
ously remodel the skeleton to maintain optimal bone structure (Kular
et al., 2012). Cathepsin K is one of the fundamental enzymes in osteo-
clastic bone resorption (Krake et al., 1996; Rantakokko et al., 1996,
Littlewood-Evans et al., 1997). CSTB is a known inhibitor of cathepsin
K and an in vitro study has shown that it has a role in regulating bone
resorption by inhibiting cathepsin K activity and osteoclast apoptosis
(Laitala-Leinonen et al., 2006). Overexpression of cathepsin K is
known to accelerate the resorption cycle (Morko et al., 2009) and to
lead to thickening of cortex in long bone (Morko et al., 2005). The
ossiﬁcation of the calvaria and phalanges is different from rest of the
skeleton and Suoranta et al. (2012) proposed that the bone changes in
EPM1 patients, most importantly, the thickening of the skull and
arachnodactyly, could be mediated through the lack of cathepsin K
inhibition, caused by reduced CSTB in cells and this would lead to
altered osteoclast function.
Here we utilized the Cstb−/− mouse model to evaluate the role of
CSTB in bonemetabolism and especially in osteoclastic bone resorption
by combiningmicro-computed tomography (μCT)with histological and
immunohistochemical analysis of bone tissue and by characterizing
bonemarrow-derived cultured osteoclasts. Our results show alterations
in bone structure of Cstb−/−mice and imply impaired formation of ma-
ture osteoclasts with consequently compromised resorptive capacity as
key phenomena contributing to the altered bone properties.
2. Materials & methods
2.1. Mouse model
Cstb−/− mice (Sv129-Cstbtm1Rm/J; stock 003486; Jackson Laborato-
ries) between 1 of 4 months of age and wild-type animals of same gen-
der and background as controls were studied. Animals weremaintained
under a 12 h light/12 h dark cycle, temperature 22± 1 °C, andwith free
access to food and water. The experiments were approved by the Ani-
mal Experiment Board of Finland (permits ESLH-2007-05788/Ym-23,
ESAVI-2010-07744/Ym-23 and ESAVI/7039/04.10.03/2012) and con-
ducted in agreement with the guidelines set by the European Commu-
nity Council Directives 86/609/EEC.
2.2. Micro-computed tomography
Ex vivo micro-computed tomography (μCT) with SkyScan 1070 μm
CT scanner (SkyScan, Kontich, Belgium) was performed on the right
hind limb of 3-month-old male mice (Cstb−/−, n = 5; controls, n =
4). Animals were perfusion ﬁxed with 4% paraformaldehyde and hind
limbs post ﬁxed for 24 h, then stored immersed in 70% EtOH. The
ﬁxed hind limbs were inserted into a sealed tubular plastic imaging
holder (manufactured in-house). The following parameters were used
for the scanning: voxel resolution 20 μm; X-ray tube potential 70 kVp;
current 200 μA; and integration time 3900 ms. The object was rotated
in 0.45° steps (total 182.45°). Cross-sectional image reconstruction
usingNrecon software version 1.4 (SkyScan, Kontich, Belgium)was per-
formed with the following parameters: misalignment b3, ring artifact
reduction 11, beam hardening correction 95% and intensity gap
0.005–0.150. Analysis and modeling were performed using CTan ver-
sion 1.4.4 (SkyScan, Kontich, Belgium). Cross-sectional images were
binarized using an attenuation coefﬁcient range of 0.005 to 0.150. Intrabecular bone, a volume of interest (VOI) excluding the cortical bone
was deﬁned at the metaphysis of the tibia, starting 20 layers (400 μm)
below the lowest point of the growth plate and covering 50 layers
(1000 μm). Cortical bone analysis was done from diaphysis of the fe-
murs, with VOI starting 200 layers (4000 μm) above the growth plate
and covering 100 layers (2000 μm). Finally, the 3D, 2D and bonemineral
density results were calculated into numerical data, with low and high
threshold values set to 35 and 250 respectively, after which the data
were analyzed.
2.3. Bone histology
2.3.1. Samples
Bonehistologywas performed on the hind limbs of Cstb−/− and con-
trol mice, age 1 month (Cstb−/−, n = 13; controls; n = 13) and 4
months (Cstb−/−, n = 13; controls, n = 13) Animals were perfusion
ﬁxed with 4% paraformaldehyde, hind limbs removed and post ﬁxed
for 24 h, then stored immersed in 70% EtOH. Samples were prepared
from distal femurs and proximal tibias, and the bones were decalciﬁed
in 5% formic acid, embedded in parafﬁn and cut into 5 μm-thick sections
for mounting on microscopy slides. Femur length was also determined
using a micrometer (Cstb−/−, n = 5; controls, n = 3).
2.3.2. Quantiﬁcation of bone morphology
Bone morphology was analyzed using hind limb samples from
1-month-old animals (Cstb−/−, n = 8; controls, n = 8). Quantitative
analysis of the thickness of the growth plate and its proliferative- and
hypertrophic zones was performed as previously described (Nurmio
et al., 2011). Brieﬂy, bone sections were stained with hematoxylin and
quantiﬁed using Leica QWin Pro analysis system (Leica Microsystems
GmbH, Wetzlar, Germany). The number of mature tartrate-resistant
acid phosphatase (TRACP, stained with the leukocyte acid phosphatase
kit (SigmaAldrich, St. Louis,Missouri, USA)) positivemultinucleated os-
teoclasts was counted as described previously (Laitala-Leinonen et al.,
2006) from samples taken from 1-month-old (Cstb−/−, n = 13; controls,
n = 13) and 4-month-old animals (Cstb−/−, n = 13; controls; n = 13).
2.4. Characterization of cultured osteoclasts
2.4.1. Bone marrow-derived osteoclast cultures
Osteoclasts were cultured as described previously (Laitala-Leinonen
et al., 2006). In brief, animals were euthanizedwith CO2 and decapitated.
Bone marrow was harvested from both femurs and tibias, and homoge-
nized to a single cell suspension. The cell suspension was then allowed
to adhere for 4 h, after which the non-adhering cells, including the mac-
rophage precursors, were plated at 100,000 cells/well on 96-well plates
in α-MEM. The culture medium was supplemented with macrophage
colony stimulating factor (M-CSF) 20 ng/ml (RnD systems, Minneapolis,
MN, USA), which induces the hematopoietic stem cells to differentiate
intomacrophages. Every 48hhalf of themediawas replaced and receptor
activator of nuclear factor kappa-B ligand (RANKL, Peprotech, Offenbach,
Germany) 100 ng/ml was added to facilitate osteoclast differentiation.
2.4.2. TRACP staining of cultured osteoclasts
First, osteoclast morphology and number was determined from
cultures.
The osteoclasts were cultured for 6 days on RANKL, after which they
were ﬁxed with 4% PFA and stained with the leukocyte acid phospha-
tase kit (Sigma Aldrich, St. Louis, Missouri, USA). For determining the
number and the area of mature osteoclasts, the samples were imaged
using Olympus ScanR system (Olympus GmbH, Hamburg, Germany), a
modular epiﬂuorescence microscope designed for fully automated
image acquisition. The number of mature osteoclasts, deﬁned a
TRACP-positive multinuclear (three or more nuclei) cells, was counted
from 22 wells for both Cstb−/− and wild type controls (cells pooled
from 3 mice per group in three independent experiments). The size of
Table 1
Quantiﬁed morphology derived from the μCT of trabecular bone in hind limbs of 3 month
old Cstb−/− and control mice.
Cstb−/− Control
Trabecular bone mineral density 0.34 ± 0.02 0.24 ± 0.01⁎
Cortical bone mineral density 0.21 ± 0.01 0.19 ± 0.06
Percent bone volume (%) 24.7 ± 1.18 18.3 ± 0.61⁎
Trabecular thickness (mm) 0.17 ± 0.01 0.14 ± 0.01⁎
Structure model index 1.30 ± 0.35 0.26 ± 0.18⁎
Trabecular number (1/mm) 1.43 ± 0.09 1.33 ± 0.03
Trabecular separation (mm) 0.54 ± 0.01 0.56 ± 0.01
⁎ p b 0.05.
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(cells pooled from 4mice per group). The quantiﬁcationwas done using
ImageJ version 1.48 ROI-manager plugin (http://rsbweb.nih.gov/).
2.4.3. Quantitative real-time PCR
Total RNA was isolated from osteoclasts (Cstb−/−mice n = 3; con-
trol mice, n = 3, all male, cells pooled) cultured for 6 days on RANKL
using Qiagen RNAeasy kit (Qiagen, Heiden, Germany) following the in-
structions of themanufacturer. Qiagen RT2 Proﬁler PCR Array osteogen-
esis kit (Qiagen, Hilden, Germany) was then used to assess gene
expression differences in Cstb−/− osteoclasts compared to controls
(136 ng of RNA used for both groups). The results were analyzed
using Qiagen RT2 Proﬁler data analysis web portal (Qiagen, Hilden,
Germany).
2.4.4. Cathepsin K assay in cultured osteoclasts
Osteoclasts were cultured for 5 days in the presence of RANKL, after
which the activity of cathepsin K was assessed using the Magic Red
Cathepsin K assay Kit (Immunochemistry Technologies, Bloomington,
MN, USA) according to the manufacturer's instructions. The ﬂuores-
cence was measured from 8 sample wells of both Cstb−/− and controls
(cells pooled from 4 mice per group) using Pherastar FS plate reader
(BMG Labtech, Ortenberg, Germany). A reference number of cells per
well was counted from a 10× ﬁeld obtained using an Incyte Zoom
(Essen Bioscience, Ann Arbor, MI, USA) system. The number of cells
per ﬁeld was determined with ImageJ version 1.48 using Analyze
Particles plugin.
2.4.5. Osteoclast pit formation assay
For assaying resorption pit formation, osteoclasts were cultured on
96-well Corning osteo-assay surface plates (Corning, New York, NY,
USA) that contain a synthetic bone coating. Culturing and analysis
were performed according to manufacturer's recommendations. In
brief, 300,000 cells/well were plated in α-MEM including M-CSF
20 ng/ml (RnD systems, Minneapolis, MN, USA). Every 48 h half of the
media was replaced and RANKL was added (100 ng/ml, Peprotech,
Offenbach, Germany). Cells were cultured for 7 days with RANKL to
allow osteoclasts to resorb the synthetic bone coating. The cells were
then ﬁxed with 4% PFA, washed with PBS and removed from the wells
with a 5 min treatment with 10% sodium hypochlorite, thus exposing
the resorption pits for microscopy.
According to the manufacturer recommendations, the formed re-
sorption pits were visualized by counterstaining the synthetic bone
coating with 1% toluidine blue (Sigma Aldrich, St. Louis, Missouri,
USA). As the resorption pits formed by osteoclasts extend to the bottom
of thewells, toluidine blue stainingmakes resorption pits readily visible
as clear regions against the dark stained background of the synthetic
bone coating. The stained samples (Cstb−/−, 10 wells; controls, 10
wells, cells pooled from 4mice per genotype) were imaged with Olym-
pus ScanR (Olympus GmbH, Hamburg, Germany). A matrix of 6 × 8 im-
ages per well at 10× magniﬁcation were obtained. For counting the
number and size of the resorption pits, proprietary ScanR software
(version 1.3.0.3, Olympus GmbH, Hamburg, Germany) was used. The
edges of the resorption pits were detected using the edge-detection
feature in the software that is based on large image intensity difference
between the dark synthetic bone and the light resorption pit. From
these detected objects, positive hits for resorption pitswereﬁrstﬁltered
for object size to exclude false positive hits caused bywell edges. Then a
staining intensity threshold was used to exclude black staining artifacts
left from the toluidine blue staining.
2.5. Statistics
Statistical analyses were done with Student's t-test using Microsoft
Excel for Mac 2011 (Microsoft, Redmond, Washington, USA) with a
p-value b0.05 considered signiﬁcant.3. Results
3.1. Altered bone structure and osteoclast homeostasis in Cstb−/−mice
To investigate the contribution of deﬁcient CSTB function on bone
metabolism we ﬁrst analyzed the bone structure in hind limbs of
3 month old Cstb−/− mice with μCT. Analysis of the trabecular bone
mineral density (BMD) revealed signiﬁcantly higher BMD in Cstb−/−
mice (0.339± 0.02 vs. control 0.243± 0.01, p = 0.001). The difference
in BMD of cortical bone was not signiﬁcant (Cstb−/− 0.208 ± 0.01 vs.
control 0.189 ± 0.06). Analysis of bone structure revealed changes in
trabecular bone (Table 1), including increased bone volume (bone vol-
ume/tissue volume) and trabecular thickness. These data indicate that
the lack of CSTB in the Cstb−/−mouse results in increased bonemass es-
pecially in the trabecular bone. As trabecular number and trabecular
separation did not show statistically signiﬁcant difference, it would ap-
pear that the change in bone volume is due to increased trabecular
thickness.
Asmany of the bone changes observed in the EPM1 patients, such as
arachnodactyly and assessory ossicles of the foot, are connected to skel-
etal growth, we next measured growth plate thickness from ﬁxed and
decalciﬁed hind limb sections. The Cstb−/−mice had signiﬁcantly thin-
ner growth plates in both distal femurs and proximal tibias already at
1 month compared to controls (Fig. 1), giving further evidence for
CSTB being required for normal skeletal growth. However, as no differ-
ences between Cstb−/− andwild-type animals were seen in thickness of
proliferative or hypertrophic zones, it appears that the structure of the
growth plates remains unaffected. Nevertheless, even thought Cstb−/−
mice have been reported to be smaller andweighting less, no difference
in femur length was observed (Cstb−/− 14.9 mm ± 1.7 vs. control
16.3 ± 0.0).
Quantiﬁcation of bone morphology showed signiﬁcantly thin-
ner growth plates in both distal femurs and proximal tibias of
Cstb−/− mice (n = 8) when compared to controls (n = 8), but no
difference in thickness of proﬁlerative or hypertrophic zones.
*p b 0.05.
To further investigate the underlying causes for the changes in bone
morphology observed in μCT and analysis of growth plate thickness, the
number of osteoclasts was ﬁrst quantiﬁed from TRAPC-stained sections
of ﬁxed and decalciﬁed hind limb bone tissue. The analysis revealed a
signiﬁcantly lower number of osteoclasts per microscopy ﬁeld in
Cstb−/− mice (Fig. 2). The difference was observed in both 1-month-
old and 4-month-old animals both in distal femurs and proximal tibias.
There was no difference in the number of osteoclasts per microscopy
ﬁeld between tibias and femurs.
A.) Quantiﬁcation of mature osteoclast numbers per microscopy
view from TRAPC-stained decalciﬁed bone section from distal femurs
and proximal tibias of 1-month-old (Cstb−/−, n = 13; controls, n =
13) and 4-month-old animals (Cstb−/−, n = 13; controls, n = 13)
shows a signiﬁcant decrease in osteoclasts numbers in Cstb−/− mice
when compared to controls.
Fig. 1. Growth plates are thinner in Cstb−/−mice.
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osteoclasts
As analysis of bone tissue suggested an osteoclast phenotype in
Cstb−/− mice, we further characterized the osteoclasts in bone mar-
row-derived osteoclast cultures. In line with the lower osteoclast
count in bone tissue, culturing non-adherent bone marrow cells from
Cstb−/−mice resulted in lower number of multinucleated TRACP posi-
tive osteoclasts than cells from control mice (Fig. 3). The size of cultured
osteoclast was signiﬁcantly smaller in Cstb−/− compared to control
cultures (Fig. 3).
A. and B.) A representative 3 × 3 matrix of microscopy ﬁelds (10×
magniﬁcation) from bone marrow-derived osteoclast cultures. For
identifying mature multinucleated osteoclasts, cultures have been
stained for TRACP (black stain on light microscopy) and Hoechst (over-
laid blue ﬂuorescence), and show lower osteoclast number and size in
the Cstb−/− group. C.) Quantiﬁcation of osteoclast cultures show signif-
icant decrease in both the size (Cstb−/−, n = 9 wells; controls, n = 9
wells) and the number (Cstb−/−, n = 22 wells; controls, n = 22
wells) of Cstb−/− osteoclasts (*p b 0.05).
To reveal possible causes for the lower osteoclast number in Cstb−/−
micewe characterized the composition of theprogenitor cell population
in bonemarrow aswell as the viability and presence of apoptosis in cul-
tured osteoclasts (Supplementary data). A smaller hematopoietic pre-
cursor population was hypothesized to lead to changes in the number
of mature osteoclasts, but the number of hematopoietic precursors
was actually slightly higher in the Cstb−/− mice. No indication for
changes in viability or apoptosis of cultured osteoclasts was observed.
Finally, qPCR-based gene expression proﬁling of cultured osteoclasts
was performed to investigate whether gene expression changes could
implicate possible causes for the difference in osteoclast numbers.Fig. 2. Histology shows decreased osteoclast numbers and increased staining intensity of
TRACP 5b and cathepsin K in Cstb−/−mice.
Fig. 3. The number and size of bone marrow-derived cultured osteoclasts is lower in
Cstb−/− than control mice.Expressions of 84 genes related to osteogenesis and bone mineral
metabolism were assayed (Supplementary Table 1). Of these, 21 were
upregulated with a fold change of ≥1.5 and 17 were downregulated
with a fold change of ≤−1.5 (Table 2). The function of the genes show-
ing altered expression was related to cell growth, differentiation and
osteoclastic function.
Gene expression proﬁling showed a 1.87 fold upregulation of
cathepsin K gene expression (Table 2) in line with the higher staining
intensity of cathepsin K (Supplementary data) in bone tissue. To inves-
tigate this further, we ﬁrst measured cathepsin K activity from cultured
Table 2
Genes showing at least 1.5-fold expression changes in Cstb−/− osteoclasts compared to
controls.
Gene Fold upregulation Gene explanation
Comp 4.65 Cartilage oligomeric matrix protein
Col10a1 4.25 Collagen, type X, alpha 1
Mmp9 3.96 Matrix metallopeptidase 9
Mmp8 3.52 Matrix metallopeptidase 8
Gli1 3.40 GLI-Kruppel family member GLI1
Cd36 3.24 CD36 antigen
Bmpr1b 2.51 Bone morphogenetic protein receptor, type 1B
Itga2 2.32 Integrin, alpha 2
Egf 2.17 Epidermal growth factor
Col2a1 1.93 Collagen, type II, alpha 1
Fgf2 1.93 Fibroblast growth factor 2
Itgam 1.89 Integrin, alpha M
Ctsk 1.87 Cathepsin K
Tnfsf11 1.76 Tumor necrosis factor (ligand) superfamily, member 11
Col4a1 1.69 Collagen, type IV, alpha 1
Spp1 1.69 Secreted phosphoprotein 1
Tgfb1 1.61 Transforming growth factor, beta 1
Icam1 1.59 Intercellular adhesion molecule 1
Tgfbr1 1.55 Transforming growth factor, beta receptor 1
Smad1 1.53 SMAD family member 1
Vegfb 1.51 Vascular endothelial growth factor B
Gene Fold downregulation Gene explanation
Bmp3 −8.02 Bone morphogenetic protein 3
Bglap −4.21 Bone gamma carboxyglutamate protein
Bmp4 −4.12 Bone morphogenetic protein 4
Bmp1 −2.54 Bone morphogenetic protein 1
Ihh −2.16 Indian hedgehog
Fgfr2 −2.11 Fibroblast growth factor receptor 2
Gdf10 −2.08 Growth differentiation factor 10
Sost −1.99 Sclerostin
Bmp2 −1.90 Bone morphogenetic protein 2
Fgf1 −1.87 Fibroblast growth factor 1
Pdgfa −1.81 Platelet-derived growth factor alpha polypeptide
Csf3 −1.75 Colony stimulating factor 3
Nog −1.69 Noggin
Runx2 −1.64 Runt related transcription factor 2
Sox9 −1.62 SRY (sex determining region Y)-box 9
Acvr1 −1.50 Activin A receptor, type I
Dlx5 −1.50 Distal-less homeobox 5
Fig. 4. Osteoclast pit formation assay indicates lower resorption by Cstb−/− osteoclasts.
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malized to the number of cells was not signiﬁcantly different between
Cstb−/− and control osteoclasts (Cstb−/− 0.82 vs. control 1.00 ﬂuores-
cence units, t-test p = 0.15).
We then studied the resorption capacity of osteoclasts thatwere cul-
tured on synthetic bone coating and assayed the number of resorption
pits formed. The number and size of the formed resorption pits was
found to be signiﬁcantly lower in the Cstb−/− group compared to con-
trol cultures (Fig. 4). As resorption capacity of individual cells seems
not to be compromised, as indicated by staining of the cathepsin K
and of TRACP 5b in bone tissue (Supplementary data), the results sug-
gest that the reduced bone resorption in the Cstb−/− cultures results
from the lower osteoclast count.
A. and B.) A representative 2 × 2 matrix of microscopy ﬁelds (10×
magniﬁcation) obtained from a resorption pit formation assay per-
formed with bone marrow-derived osteoclast cultures. The assay dem-
onstrates that smaller and fewer resorption pits are formed by Cstb−/−
osteoclasts. Osteoclasts cultured on synthetic bone coating form resorp-
tion pits that extend to the bottom of thewell. When the synthetic bone
is counterstained with toluidine blue (dark stain), the pits are observed
as light areas (indicated by black arrows). The black staining artifacts
are caused by toluidine blue. C.) Quantiﬁcation of the resorption pits
(Cstb−/− n = 10 wells; controls, n = 10 wells) shows that Cstb−/− os-
teoclasts form signiﬁcantly less and smaller pits compared to controls.
*p b 0.05.4. Discussion and conclusions
We investigated the cause for the skeletal changes observed in EPM1
patients and the role of CSTB in bone tissue by characterizing the bone
and osteoclast phenotype in the Cstb−/− mouse model of EPM1. This
model recapitulates well the key neurological and neuropathological
features of the human disease, (Pennacchio et al., 1998, Kälviäinen
et al., 2008, Manninen et al., 2013, Tegelberg et al., 2012) but the bone
phenotype of Cstb−/− mice had not been studied before. Analysis of
bone morphology and composition with μCT revealed thicker and
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no differences in cortical bone structure were seen. In EPM1 patients,
the diffuse skull thickening affects also the trabecular bone (Korja
et al., 2007, Suoranta et al., 2012). While the implied osteoporotic
changes in calvarial bones of EPM1 patients could indicate decreased
BMD, but, due to the retrospective study setup, no BMDmeasurements,
or quantiﬁcation of structural changes were performed (Suoranta et al.,
2012).
The other bone changes reported in EPM1 patients, e.g. scoliosis,
arachnodactyly and the presence of accessory ossicles in the feet, are
linked to skeletal formation (Suoranta et al., 2012). However, no
obvious macroscopic morphological bone changes were identiﬁed in
Cstb−/− mice. While osteoblast cultures did not indicate apparent dif-
ferences in bone formation between Cstb−/− and control mice (Supple-
mentary data), analysis of growth plate thickness revealed them to be
signiﬁcantly thinner in Cstb−/−mice. Taken together these data suggest
that changes in bone growth and remodeling contribute to the observed
skeletal changes in the EPM1 patients. The contribution of medication,
especially of phenytoin that has been reported to cause calvarial thick-
ening (Kattan, 1970) and of the reduced mobility due to incapacitating
myoclonus of the EPM1 patients to the observed bone changes has pre-
viously been discussed (Suoranta et al., 2012). However, as the bone
phenotype is present already in young mice and in in vitro systems,
our results in Cstb−/−mice indicate that the bone changes in EPM1 pa-
tients are a direct result of deﬁcient CSTB function.
The cell cultures from Cstb−/−mice have not indicated an osteoblast
phenotype in Cstb−/−mice that would contribute to the observed mor-
phological change (Supplementary data), however bone histology and
bone marrow-derived osteoclastic cultures revealed fewer osteoclasts
of smaller size in Cstb−/− mice compared to control mice. This could
be caused by lower progenitor cell population, lower viability, failure
in differentiation and/or maturation or increased death of osteoclasts
in Cstb−/−mice. However, the bone marrow progenitor cell population
was slightly larger in Cstb−/− animals and no signiﬁcant differences in
cell viability between Cstb−/− and controlmicewere observed. Further-
more, even if previous reports have shown that CSTB is capable of
inhibiting osteoclast apoptosis and regulate bone resorption in vitro
(Laitala-Leinonen et al., 2006), and that cathepsin K modulates osteo-
clastic apoptosis and senescence (Chen et al., 2007, Wilson et al.,
2009), no differences were seen in the apoptotic death of osteoclasts
between Cstb−/− and control mice. The signiﬁcantly smaller size of
cultured Cstb−/− osteoclasts, however, implies a failure in the fusion
and/or differentiation of the precursor cells to mature osteoclast. Inter-
estingly, qPCR-based expression proﬁling of genes relevant to osteogen-
esis revealed altered expression of several genes related especially to
osteoclastic differentiation and function. All seven bone morphogenic
proteins (BMPs), known to stimulate osteoclast differentiation and sur-
vival (Itoh et al., 2001, Okamoto et al., 2006, Wutzl et al., 2006) in the
assay were downregulated in Cstb−/− cultures. Of these, BMP3 showed
8-fold downregulation. Activin A receptor 1, which relays BMP signals
and is known to play an important role in osteoclast differentiation
(Fuller et al., 2000), was downregulated 1.5-fold. Genes related to the
resorptive function such as cathepsin K and matrix metallopeptidase 9
(MMP9), which digest the collagen matrix in bone (Reponen et al.,
1994), were upregulated. However, whether these changes in gene ex-
pression are responsible for the bone changes observed in vivo, ormere-
ly reﬂect the phenotype of the cultured cells, remains to be investigated.
CSTB is a known inhibitor of cathepsin K and immunohistochemical
analysis of osteoclasts in distal femurs and proximal tibias indicated
higher cathepsin K expression in Cstb−/− mice (Supplementary data).
Also, CSTB has been reported suppressing resorption by osteoclasts
in vitro (Laitala-Leinonen et al., 2006). Contrary to these results, the
pit formation assay showed that the overall resorption capacity, at
least in vitro, is signiﬁcantly compromised in the Cstb−/− osteoclasts.
Therefore, increased TRACP 5b and cathepsin K staining in bone tissue
(Supplementary data), combined with elevated cathepsin K geneexpression in Cstb−/− osteoclasts could be an indication of a compensa-
tory mechanism to the inadequate resorptive function. Nevertheless,
resorption pit formation assay has been shown to be a good quantitative
measure of osteoclast resorption activity (Fuller et al., 1994), and de-
crease in osteoclast numbers has previously been linked with an in-
crease in trabecular thickness and BMD (Boyce et al., 2014). As
resorptive function of osteoclasts is closely linked to the cell size and
number (Xing et al., 2012), the impaired resorptive function suggests
that the changes in bone morphology, e.g., more heavily mineralized
bone and the thicker trabeculae result from lower osteoclast number
and size. Therefore, we feel safe to conclude that the changes in bone
morphology in the Cstb−/−mice, and of EPM1 patients, result from in-
adequate resorptive capacity of osteoclasts due to their decreased num-
ber and size, which is likely to be caused by impaired formation of
mature osteoclasts.
In light of the recent ﬁndings in Cstb−/−mice linking CSTB function
to inﬂammation (Maher et al., 2014, Okuneva et al., 2015) it is possible
that inﬂammatory mechanisms contribute to the altered bone homeo-
stasis. Interestingly, epigenetic processes were recently linked to differ-
entiation of osteoclasts, the defect of which resulted in an osteoclast and
bone phenotype resembling that of Cstb−/− mice (Nishikawa et al.,
2015). Therefore, as CSTB is known to have a nuclear localization and
function (Alakurtti et al., 2005, Ceru et al., 2010), similar mechanisms
could be involved in EPM1 as well. While the mechanism by which
lack of CSTB leads to observed skeletal changes remains to be identiﬁed,
our results nevertheless suggest that the role of CSTB in osteoclasts is
more complex than simply acting as an inhibitor of cathepsin K.
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